Effects of transdermal estrogen therapy on expressions of estrogen receptors and T-lymphocyte apoptosis in surgically menopausal women

Cellular and Molecular Immunology

Volumn 6, Issue 4, 2009, Pages 277-283

  Zhang, Jing ^a   Chen, Xing ^a   Zhang, Shaofen ^a   Zhou, Guangyan ^b   Xia, Xian ^a   Lu, Liming ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Estrogen receptor; Estrogen replacement therapy; Surgical menopause; T lymphocyte apoptosis

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FAS ANTIGEN; FAS LIGAND; FOLLITROPIN; ESTROGEN RECEPTOR; ESTROGEN; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; PROSTAGLANDIN E2;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HYSTERECTOMY; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE; PROTEIN EXPRESSION; QUALITY OF LIFE; QUESTIONNAIRE; RECEPTOR UPREGULATION; SALPINGOOOPHORECTOMY; T LYMPHOCYTE; VENOUS BLOOD; AGING; CD3+ T LYMPHOCYTE; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; IMMUNE RESPONSE; IMPROVED KUPPERMAN INDEX; LOW DRUG DOSE; MENOPAUSE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; PROTECTION; SCORING SYSTEM; TREATMENT DURATION; UTERUS MYOMA; BLOOD; DRUG EFFECT; EARLY MENOPAUSE; GENETICS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIGENS, CD95; APOPTOSIS; DINOPROSTONE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FAS LIGAND PROTEIN; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MENOPAUSE, PREMATURE; MIDDLE AGED; RECEPTORS, ESTROGEN; T-LYMPHOCYTES;

EID: 69949130528     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.37     Document Type: Article

References (22)

1. Archer DF. Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2003;10:516-521. (Pubitemid 40228145)
2. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353:571-580.
3. Solerte SB, Floravanti M, Racchi M, Trabucchi M, Zanetti O, Govoni S. Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis. Maturitas. 1999;31:95-101. (Pubitemid 29074377)
4. Popp AW, Bodmer C, Senn C, et al. Prevention of postmenopausal bone loss with longcycle hormone replacement therapy. Maturitas. 2006;2:191-200.
5. Kumru S, Godekmerdan A, Yilmaz B. Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women. J Reprod Immunol. 2004;63:31-38. (Pubitemid 38988251)
6. Porter VR, Greendale GA, Schocken M, et al. Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol. 2001;36:311-326. (Pubitemid 32162484)
7. Fahlman MM, Boardley D, Flynn MG, et al. Effects of hormone replacement therapy on selected indices of immune function in postmenopausal women. Gynecol Obstet Invest. 2000;50:189-193. (Pubitemid 30759480)
8. Takao T, Kumaqai C, Hisakawa N, et al. Effect of 17β-estradiol on tumor necrosis factor-alpha-induced cytotoxicity in the human peripheral T lymphocytes. J Endocrinol. 2005;184:191-197. (Pubitemid 40207573)
9. Phiel KL, Henderson RA, Adelman SJ, et al. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. 2005;97:107-113. (Pubitemid 40038861)
10. Akhila V, Pratapkumar. A comparison of transdermal and oral HRT for menopausal symptom control. Int J Fertil Womens Med. 2006;51:64-69.
11. Simon JA, Bouchard C, Waldbaum A, et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;109:588-596. (Pubitemid 46339398)
12. Issued on behalf of the board of the international menopause society. IMS updated recommendation on postmenopausal hormone therapy. Climacteric. 2007;10:181-194.
13. Ivory K, Martin R, Hughes DA. Significant presence of terminally differentiated T cells and altered NF-κB and I-κBα interactions in healthy ageing. Exp Gerontol. 2004;39:567-576. (Pubitemid 38404283)
14. + T cells in aged humans. Exp Gerontol. 2006;41:69-77
15. + T cells in aged humans. Exp Gerontol. 2008;43:266-274.
16. Hirano S, Furutama D, Hanafusa T. Physiologically high concentrations of 17β-estradiol enhance NF-κB activity in human T cells. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1465-1471. (Pubitemid 46557806)
17. Zajchowski S, Hoffman-Goetz L. Supraphysiological level of estrogen exposure in vivo increases lymphoid cell death in mice. Life Sci. 2000;66:1451-1459 (Pubitemid 30152316)
18. Waring P, Müllbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol. 1999;77:312-317. (Pubitemid 29370101)
19. + T lymphocytes. Int Immunol. 2000;12:195-203.
20. Aggarwal S, Gupta S. Increased apoptosis of T cell subsets in aging human: altered expression of Fas (CD95), Fas ligand, Bcl-2 and Bax. J lmmunol. 1998;160:1627-1637. (Pubitemid 28106447)
21. Mor G. Sapi E. Abrahams VM, et al. Intraction of the-estrogen receptor with the Fas ligand promotor in human monocytes. J Immunol. 2003;170:114-122. (Pubitemid 36026130)
22. Shim GJ, Gherman D, Kim HJ, et al. Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol. 2006;208:408-414. (Pubitemid 43210528)